09:42 AM EDT, 09/10/2025 (MT Newswires) -- Hims & Hers Health ( HIMS ) said Wednesday it launched a new men's health category focused on treatment plans for low testosterone.

The company said that providers can begin prescribing new personalized care options such as compounded enclomiphene, which stimulates natural testosterone production, and a combined enclomiphene-tadalafil therapy for men with sexual symptoms, starting Wednesday.

Customers will begin with at-home blood tests and consult licensed providers for tailored care plans, Hims said.

In 2026, Hims plans to offer Kyzatrex, an oral testosterone drug approved by the US Food and Drug Administration and developed by Marius Pharmaceuticals, alongside injectable testosterone treatments, the company added.

Shares of the company were up more than 4% in early trading Wednesday.

Price: 49.70, Change: +1.97, Percent Change: +4.12